References Baggio, L
The drug targets three receptors involved in energy balance and metabolism: GLP-1 (glucagon-like peptide-1) receptor GIP (glucose-dependent insulinotropic polypeptide) receptor Glucagon receptor By activating these pathways, the therapy aims to: Reduce appetite Improve insulin regulation Increase metabolic activity and energy expenditure This triple-receptor mechanism distinguishes retatrutide from earlier metabolic drugs that target only one or two pathways
Type 2 diabetes (formulation R2) Starting (Day 1 to 30): 1.5 mg once daily for 30 days (this dosage is not effective for glycemic control) Escalation and Maintenance Dosage: Days 31 to 60: Increase the dosage to 4 mg orally once daily Day 61 and on: If blood sugars are controlled, continue 4 mg once daily
Retatrutide is being studied in that same general category of peptide weight loss therapy , but with an important twist: it is designed as a triple-agonist. What that means is that retatrutide targets three receptors involved in weight regulation and metabolism: GLP-1 , which supports satiety and improves glucose control GIP , another incretin hormone involved in metabolic signaling Glucagon receptors , which are linked to energy balance and how the body uses fuel This three-pronged approach is a big reason its creating buzz
Patches and non-Wegovy pills, marketed for weight loss, are not yet FDA-regulated
Ready to see your transformation at 1, 3, and 6 months
